Trial Profile
A Single Center, Open-label, Randomized, Two-period Crossover Food Effect Study of Single Doses of Fruquintinib (HMPL-013) in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Jul 2019
Price :
$35
*
At a glance
- Drugs Fruquintinib (Primary)
- Indications Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Hutchison MediPharma
- 01 Jul 2019 Results assessing pharmacokinetics profile of fruquintinib after single-dose administration in healthy subjects published in the Clinical Therapeutics
- 24 Mar 2018 Results assessing pharmacokinetics of fruquintinib by using data from two studies including this study presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 13 Oct 2013 New trial record